Biotricity Approves 1-for-100 Reverse Stock Split to Meet Listing Requirements

summarizeSummary

Biotricity Inc. has approved a 1-for-100 reverse stock split, a move supported by its CEO and major Series C Preferred stockholders, to boost its share price and pursue a NASDAQ listing.

check_boxKey Events

• 1-for-100 Reverse Stock Split Approved

  The Board of Directors and a majority of Series C Preferred stockholders, including CEO Waqaas Al-Siddiq and his family, have approved a 1-for-100 reverse stock split by written consent.

• Purpose: NASDAQ Listing and Marketability

  The primary goal is to increase the per-share price to meet NASDAQ Capital Markets listing requirements and improve the stock's marketability, addressing its current 'penny stock' classification.

• Fractional Shares Rounded Up

  Any fractional shares resulting from the reverse split will be rounded up to the nearest whole share.

• Authorized Shares Unchanged

  The total number of authorized common shares will remain the same, which could lead to significant potential dilution if new shares are issued at the post-split price.

auto_awesomeAnalysis

The company's Board and a majority of Series C Preferred stockholders, including the CEO and his family, have approved a highly aggressive 1-for-100 reverse stock split. This action is critical for Biotricity, a company that previously reported a 'going concern' warning, as it aims to significantly increase its per-share price to potentially qualify for a NASDAQ Capital Markets listing and escape its 'penny stock' classification. While intended to improve marketability and access to capital, such a drastic reverse split often signals underlying financial distress and can lead to further share price erosion post-split. The unchanged number of authorized shares post-split also creates substantial headroom for future dilution.